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Alzheimer’s disease (AD) is associated with the deposition of b-amyloid (Ab) plaques in the brain. In
this issue, by cleverly processing patient samples, Lu et al. define a novel structural model of Ab
fibrils from AD brain, revealing surprising differences from in vitro fibrils. These findings may lead
to structure-specific inhibitors and more selective amyloid-imaging methods.Alzheimer’s disease (AD) is the most
common neurodegenerative disorder,
affecting 35 million people worldwide.
This number is predicted to skyrocket
with the aging ‘‘baby boomer’’ popula-
tion. The pathological hallmark of AD is
the presence of extracellular neuritic
plaques comprised of b-amyloid (Ab) pep-
tides, cleavage products of the amyloid
precursor protein (APP), consisting of
39–43 residues. Hence, a detailed struc-
tural understanding of Ab aggregation in
AD patients would greatly help the rational
design of drugs. In this issue, Lu et al. pre-
sent structural analyses of Ab fibers
derived from patient brain samples; their
analyses suggest new avenues for
tailored diagnostics and therapies.
Accumulation of Ab in the brain is likely
the cause of AD (Hardy and Selkoe,
2002). Indeed, genetic mutations that
cause familial AD enhance the production
of Ab. These lesions include mutations in
the APP gene, which result in a more amy-
loidogenicprotein or in thepresenilins (PS1
or PS2) that encode components of the g-
secretase enzyme that processes APP to
liberate Ab peptides. Current therapeutic
strategies aim at targeting and eliminating
Ab (Gandy and DeKosky, 2013). However,
this approach remains challenging as the
precise nature of the most toxic Ab con-
formers (amyloid fibrils, oligomers of
various sizes, and/or protofibrils) is unre-
solved. Moreover, because the course
andneuropathologyofADcanvarygreatly,
distinct Ab assemblieswithin thebrainmay
lead to different clinical phenotypes.
Ab aggregates formed in vitro can show
significant structural diversity (Petkova1182 Cell 154, September 12, 2013 ª2013 Elet al., 2005), yet structures of Ab aggre-
gates in vivo have remained elusive. Are
they similar to in vitro aggregates? Are
they as polymorphic as aggregates
formed in vitro, or does one conformation
dominate at the expense of others within
AD brains?
In this issue of Cell, Lu et al. (2013)
attack this problem in an elegantway. Pre-
vious work showed that new Ab fibers
formed in a reaction using short bits of
pre-existing fibrils to act as seeds retain
the structures of the starting seeds (Kodali
et al., 2010; Petkova et al., 2005). The
authors therefore reasoned that amyloid-
containingmaterial frombrain tissuemight
seed in an in vitro fibril assembly reaction.
The structures of the fibrils formed in these
reactions would reflect those present in
the brain and may provide quantities suit-
able for atomic-scale analyses.
The paper reports the use of a newly
developed, enhanced amyloid extraction
protocol to isolate seed material from
the brain of two AD patients with distinct
clinical histories. When this material was
mixed with synthetic Ab40 peptide, long
fibrils grew within a few hours, which
could be examined using solid-state
nuclear magnetic resonance (NMR).
What came next was remarkable and
completely unexpected.
In each of the two patients, the fibrils
that grew out of a reaction seeded with
amyloid-enriched brain extract adopted a
single predominant structure, even when
extracts from different brain regions from
the same patient were used. However,
the brain-seeded fibrils from the first and
second patients differed markedly. Thus,sevier Inc.it seems that each patient had developed
structurally distinct fibrils in their brains,
raising the intriguing possibility that struc-
tural differences in Ab aggregates reflect
or perhaps underlie the differences in clin-
ical history of these patients.
The authors then amplified enough
brain-seeded Ab fibrils to perform high-
quality solid state NMR and generated a
full structural model for Ab40 fibrils from
the brain of the first patient. These studies
revealed several exciting findings. Impor-
tantly, the in vivo structural model
exhibited key differences from previously
determined models for in vitro fibrils,
including specific side-chain contacts
and new solvent exposed and buried
surfaces. The illumination of these struc-
tural insights offers a treasure trove for
the structure-based design of antagonists
of Ab aggregation.
Beyond therapeutic opportunities,
these findings may also usher in a new
generation of imaging modalities. Com-
pounds that preferentially bind amyloid
fibrils have been harnessed as positron
emission tomography (PET) ligands,
enabling in vivo imaging of amyloid depo-
sition. These imaging agents are now a
powerful tool in AD clinical research and
diagnosis and serve as beacons for clin-
ical trials of Ab-lowering therapeutics
(Gandy and DeKosky, 2013). The struc-
tural insights emerging from Lu et al.
could lead to enhanced PET ligands spe-
cific for certain structures (Figure 1). The
structures may also help clarify the
mechanism of polythiophene-based fluo-
rescent ‘‘amyloidotropic’’ dyes, which
change colors upon binding to
Figure 1. A Structure-Specific Approach to Alzheimer’s Disease
(A) Lu et al. (2013) analyzed Ab structures from twoAlzheimer’s disease patient brains, with different clinical histories. Both Alzheimer’s disease patient’s harbored
extensive Ab pathology, but perhaps the Ab aggregates formed distinct morphologies during disease (e.g., morphology A and morphology B). The authors
extracted amyloid-enrichedmaterial from brain and used this to seed in vitro Ab fibrillization reactions. Solid-state NMRwas used to determine a structural model
for the Ab aggregates from patient 1, revealing novel side-chain contacts, solvent-exposed and solvent-buried surfaces. These structural insights can be used to
develop structure-specific radioligands for in vivo amyloid imaging, as well as more selective small molecule inhibitors and therapeutic antibodies.
(B) An example of how Ab structural insights can be translated to the clinic. Different Alzheimer’s disease patients likely harbor distinct Ab aggregate structures
and thus some will respond better to certain treatments than other ones. New structure-specific PET radioligands based on insights from Lu et al. (2013) and
future follow-up studies can be used for in vivo amyloid imaging to help stratify patients. Additional biomarkers (e.g., analytes from blood or cerebrospinal fluid
[CSF]) may also be utilized to help stratify Alzheimer’s patients. Following patient stratification, structure-selective Ab inhibitors and therapeutic antibodies could
be used to treat patients with specific Ab structures.conformationally distinct aggregates (Si-
gurdson et al., 2007).
Many important questions and oppor-
tunities lay ahead. The total brain plaque
load is a notoriously poor predictor of
cognitive fitness. Might distinct Ab mor-
phologies show a better correlation with
cognition? Expanding this study to large
AD brain collections will not only illustrate
the diversity and complexity of Ab aggre-
gates but could help to define the prog-
nosis of individuals at risk for AD. Are
different morphologies selectively tar-
geted by subsets of anti-Ab antibodies?
If so, the limited success of current AD
immunotherapy may be due, at least in
part, to inadequate patient stratification,
and personalized antibodies may be
needed. Are there active mechanisms
promoting ‘‘benign’’ Ab assemblies and
are such mechanisms genetically en-
coded? If so, could small-molecule,
peptide, or antibody-based therapeutic
approaches be used to redirect Ab
misfolding trajectories toward the more
benign conformations? On the otherhand, do genetic risk factors for AD,
such as the ε4 allele of APOE, rare
variants in TREM2, and others, enhance
the formation of more disease-associated
Ab assemblies?
Many neurodegenerative diseases in-
cluding tau and Ab in AD, a-synuclein in
Parkinson’s disease, and SOD1 (and
perhaps TDP-43 and FUS) in ALS, are
caused by ‘‘prionoids,’’ protein aggre-
gates that can propagate from one cell
to another even if they are not transmis-
sible between individuals (Aguzzi and
Rajendran, 2009). Lu et al.’s findings sup-
port the view that Ab comes in discrete
strains, as has been suggested for a-syn-
uclein (Guo et al., 2013) and tau (Clava-
guera et al., 2013). However, a rigorous
(and, we believe, necessary) test of this
idea will require proof that each of
the different conformers generates new
seeds retaining the same phenotypic
‘‘strainness’’ across multiple generations,
as is the case for prion diseases and all
other infectious pathogens (Aguzzi and
Polymenidou, 2004).Cell 154, SepAlthough exciting, the new findings
should not be considered without some
caveats. Although the structural data are
consistent with each of the two AD brains
harboring just one dominant Ab structure,
that dominancemay stem from conforma-
tional selection. That is, there may be a
wealth of structures in AD brains with only
few susceptible to amplification. Even if
only one Ab structure was present at time
of autopsy, did many other fibril structures
coexist during disease progression with
one winner emerging, which propagated
throughout the brain? The structural ap-
proaches presented by Lu et al. are a great
starting point and hopefully these studies
will be extended to many more AD patient
samples in order to define the full range
of Ab structures that form in the brain dur-
ing AD pathogenesis. Finally, these types
of approaches may also provide insight
into the molecular features responsible
for prion-like templating and spreading of
protein aggregates in AD, other neurode-
generative disorders, and possibly also
systemic amyloidoses.tember 12, 2013 ª2013 Elsevier Inc. 1183
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Autophagy is a cell-autonomous, catabolic process that plays context-dependent roles in tumor
growth and progression. Wei et al. report that EGFR signaling promotes tumor growth through
phosphorylation and functional inactivation of Beclin 1 and the consequent suppression of
autophagy.Macroautophagy (hereafter termed auto-
phagy) is a degradative process that
involves the encircling of cytoplasmic
elements by a specialized endomem-
brane structure (the autophagosome),
which delivers the cargo to lysosomes
for degradation and recycling into cellular
metabolic pathways. Autophagy supports
cell survival during metabolic stress
and maintains normal homeostasis by
ridding the cell of protein aggregates
and dysfunctional organelles (Choi et al.,
2013). Although autophagy is clearly rele-
vant to cancer biology, studies to date
paint a rather muddled picture, which
indicates that autophagy either sup-
presses or promotes tumor growth,
depending on cancer subtype and the
stage of tumor development (White,
2012). The report by Wei et al. (2013) in
this issue of Cell defines a novel pathwaythrough which the epidermal growth
factor receptor (EGFR) suppresses auto-
phagic activity to promote the growth of
non-small-cell lung cancers (NSCLCs).
The core components of the autopha-
gic machinery are conserved in eukary-
otic cells. Two critical proteins involved
in the initiation of autophagy are the class
III phosphoinositide 3-kinase, VPS34, and
the protein serine-threonine kinase, ULK1
(see Figure 1). VPS34 activation leads to
the localized accumulation of phosphati-
dylinositol 3-phosphate, which stimulates
endomembrane events required for auto-
phagosome formation (Lorin et al., 2013).
VPS34 activity is regulated, in part,
through binding to Beclin 1, a scaffolding
protein that has been identified as a
haploinsufficient tumor suppressor (Choi
et al., 2013; Lorin et al., 2013). Beclin 1
governs autophagy through interactionswith proteins that either stimulate
(ATG14L, UVRAG, and AMBRA1) or sup-
press (Bcl-2, Bcl-xL, and Rubicon)
VPS34 activity. The scaffolding functions
of Beclin 1 are directly modulated by a
growing number of protein kinases,
including mTOR, AMPK, ULK1, and AKT
(Lorin et al., 2013; Russell et al., 2013).
The EGFR tyrosine kinase is overex-
pressed or mutationally activated in a
broad range of human cancers, including
NSCLC. Previous reports indicated that
EGFR activation suppresses autophagy
and that TKI exposure triggers increased
autophagic flux in NSCLC cells (Fung
et al., 2012; Han et al., 2011). However,
the interplay between EGFR signaling
and the autophagy machinery, as well as
the role of autophagy in EGFR-driven
tumor growth, remained unclear. Wei
et al. (2013) demonstrate that Beclin 1
